FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Active, not recruiting · NCT04891757 · Registry updated 2025-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2025-07-10 | NCT04891757 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Foghorn Therapeutics Inc. | 3 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope National Medical Center | Duarte | United States | 68 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Vanderbilt University Medical Center | Nashville | United States | 427 |